Transaction DateRecipientSharesTypePriceValue
23rd September 2020Group Holdings (Sbs) Advisors, Inc. Tpg229Open or private purchase$8.87$2,030.36
22nd September 2020Group Holdings (Sbs) Advisors, Inc. Tpg17,199Open or private purchase$8.78$151,031.30
22nd September 2020Group Holdings (Sbs) Advisors, Inc. Tpg47,012Open or private sale$26.41$1,241,408.27
21st September 2020Group Holdings (Sbs) Advisors, Inc. Tpg66,486Open or private sale$25.20$1,675,241.09
21st September 2020Group Holdings (Sbs) Advisors, Inc. Tpg111,002Open or private purchase$8.93$990,837.15
18th September 2020Group Holdings (Sbs) Advisors, Inc. Tpg1,200Open or private purchase$9.00$10,800.00
18th September 2020Group Holdings (Sbs) Advisors, Inc. Tpg11,213Open or private sale$27.24$305,433.15
18th September 2020Group Holdings (Sbs) Advisors, Inc. Tpg73,474Open or private sale$26.16$1,921,822.68
18th September 2020Paul Edward Walker332,964Conversion of derivative$0.00
18th September 2020Paul Edward Walker1,958,333Conversion of derivative$0.00
Trevi Therapeutics
Trevi Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease.


Ticker: TRVI
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1563880
Employees: 15
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals